Atrial fibrillation in patients with an atrial septal defect in a single centre cohort during a long clinical follow-up: its association with closure and outcome of therapy.


Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
08 2020
Historique:
received: 27 03 2020
revised: 29 05 2020
accepted: 27 06 2020
entrez: 21 8 2020
pubmed: 21 8 2020
medline: 22 12 2020
Statut: ppublish

Résumé

Currently, consensus is lacking on the relation between closure of atrial septal defect (ASD) and the incidence of atrial fibrillation (AF), which is a known complication in ASD patients. More importantly, studies reporting on the treatment applied for AF in ASD patients are scarce. The aims of this study were (1) to assess the incidence of AF in ASD patients, (2) to study the relation between closure and AF and (3) to evaluate applied treatment strategies. A single-centre retrospective study in 173 patients with an ASD was performed. We analysed the incidence of AF, the relation of AF with closure, method of closure and the treatment success of therapies applied. Almost 20% of patients with an ASD developed AF, with a mean age of 59 (±14) years at first presentation of AF during a median clinical follow-up of 43 (29-59) years. Older age (OR 1.072; p<0.001) and a dilated left atrium (OR 3.727; p=0.009) were independently associated with new-onset AF. Closure itself was not independently associated with AF. First applied treatment strategy was rhythm control in 77%. Of the 18 patients treated with antiarrhythmic drugs 50% had at least 1 recurrence of AF. No clear relation between closure of the ASD and AF could be assessed. This is the first study describing applied therapy for AF in ASD patients of which medical rhythm control was the most applied strategy with a disappointing efficacy.

Identifiants

pubmed: 32817255
pii: openhrt-2020-001298
doi: 10.1136/openhrt-2020-001298
pmc: PMC7437693
pii:
doi:

Substances chimiques

Anti-Arrhythmia Agents 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

N Engl J Med. 1999 Mar 18;340(11):839-46
pubmed: 10080846
Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):50
pubmed: 28038729
Heart. 2015 May;101(9):706-11
pubmed: 25691512
Circ J. 2013;77(1):109-15
pubmed: 23075753
J Pediatr. 2008 Dec;153(6):807-13
pubmed: 18657826
N Engl J Med. 1990 Dec 13;323(24):1645-50
pubmed: 2233961
Heart. 2010 Nov;96(22):1789-97
pubmed: 20965992
Circulation. 1994 Feb;89(2):724-30
pubmed: 8313561
Circulation. 2009 Oct 27;120(17):1679-86
pubmed: 19822808
Am J Cardiol. 2008 Oct 1;102(7):902-6
pubmed: 18805119
Heart Rhythm. 2018 Mar;15(3):341-347
pubmed: 29038089
Clin Res Cardiol. 2011 Dec;100(12):1111-7
pubmed: 21909849
J Interv Card Electrophysiol. 2015 Jan;42(1):43-9
pubmed: 25504269
Heart. 2013 Sep;99(18):1346-52
pubmed: 23886606
Heart Rhythm. 2011 Nov;8(11):1669-75
pubmed: 21703215
Circulation. 1998 Sep 8;98(10):946-52
pubmed: 9737513
Am J Cardiol. 2017 Feb 1;119(3):461-465
pubmed: 27939228
Circ Arrhythm Electrophysiol. 2015 Oct;8(5):1065-72
pubmed: 26276884
Am J Cardiol. 2002 Jan 1;89(1):39-43
pubmed: 11779520
Lancet. 2015 Jul 11;386(9989):154-62
pubmed: 25960110
J Am Coll Cardiol. 2011 Nov 15;58(21):2241-7
pubmed: 22078432
JAMA. 2001 May 9;285(18):2370-5
pubmed: 11343485
Am J Cardiol. 2008 Mar 1;101(5):683-7
pubmed: 18308021
Eur Heart J. 2006 Apr;27(8):949-53
pubmed: 16527828
Congenit Heart Dis. 2019 Nov;14(6):1123-1129
pubmed: 31692272
Ann Thorac Surg. 1999 Jul;68(1):75-8
pubmed: 10421118
J Cardiovasc Electrophysiol. 2012 Jan;23(1):102-4
pubmed: 21914020
Int J Cardiol. 2013 Apr 15;164(3):318-22
pubmed: 21802750
N Engl J Med. 1995 Aug 24;333(8):469-73
pubmed: 7623878
Can J Cardiol. 2014 Oct;30(10):e1-e63
pubmed: 25262867

Auteurs

Reinder Evertz (R)

Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands reinder.evertz@radboudumc.nl.

Manon Reinders (M)

Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.

Charlotte Houck (C)

Cardiology, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands.

Tim Ten Cate (T)

Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.

Anthonie L Duijnhouwer (AL)

Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.

Rypko Beukema (R)

Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.

Sjoerd Westra (S)

Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.

Kevin Vernooy (K)

Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.

Natasja M S de Groot (NMS)

Cardiology, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH